Stiefel introduces BPO Acne Creamy Washes for OTC use in the U.S.

Stiefel, a GSK company, today announced the launch of the most-prescribed BPO Acne Wash formulations for over-the-counter (OTC) use in the United States. The launch will occur in the technical exhibit at the American Academy of Dermatology annual meeting in New Orleans. Indicated for the treatment of acne, Stiefel will market two products OTC under the PanOxyl® Brand.  PanOxyl® Acne Creamy Wash will be available in 4% BPO and 8% BPO.  

PanOxyl® 4% and 8% BPO Acne Creamy Washes feature a patented delivery system including Dimethyl Isosorbide (DMI) that solubilizes BPO and greatly reduces particulate-based skin irritation and inflammation commonly experienced with conventional BPO formulations.  Both products are thick, creamy formulations which provide excellent efficacy and rapid reduction in acne lesions.  

"Stiefel's Creamy Wash formulations have been physician favorites for several years," said Shayne Sundholm, vice president, U.S. Non Prescription Dermatology, Stiefel.  "And we are excited to be able to offer them to a larger number of consumers through the retail market."  

A comprehensive marketing campaign directed toward dermatologists and pharmacists will communicate details of the new PanOxyl® 4% and 8% BPO Acne Creamy Washes.  Product will be available for shipment in May 2011.  

PanOxyl® Acne Management product line offers different formulations for the treatment and prevention of acne on the face, chest and back.  

SOURCE Stiefel, a GSK company